% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Pham:286989,
      author       = {T. T. Pham and K. Nimptsch and K. Aleksandrova and M. Jenab
                      and V. Fedirko and K. Wu and A. K. Eriksen and A.
                      Tjønneland and G. Severi and J. Rothwell and R. Kaaks$^*$
                      and V. Katzke$^*$ and A. Catalano and C. Agnoli and G.
                      Masala and M. S. De Magistris and R. Tumino and R. Vermeulen
                      and A. Aizpurua and C. Trobajo-Sanmartín and M.-D.
                      Chirlaque and M.-J. Sánchez and S. S. M. Lu and A. J. Cross
                      and S. Christakoudi and E. Weiderpass and T. Pischon},
      title        = {{P}re-diagnostic circulating resistin concentrations and
                      mortality among individuals with colorectal cancer:
                      {R}esults from the {E}uropean {P}rospective {I}nvestigation
                      into {C}ancer and {N}utrition study.},
      journal      = {International journal of cancer},
      volume       = {154},
      number       = {9},
      issn         = {0020-7136},
      address      = {Bognor Regis},
      publisher    = {Wiley-Liss},
      reportid     = {DKFZ-2024-00106},
      pages        = {1596-1606},
      year         = {2024},
      note         = {2024 May 1;154(9):1596-1606},
      abstract     = {Resistin is a protein involved in inflammation and
                      angiogenesis processes and may play a role in the
                      progression of colorectal cancer (CRC). However, it remains
                      unclear whether resistin is associated with increased
                      mortality after CRC diagnosis. We examined pre-diagnostic
                      serum resistin concentrations in relation to CRC-specific
                      and all-cause mortality among 1343 incident CRC cases from
                      the European Prospective Investigation into Cancer and
                      Nutrition cohort. For CRC-specific mortality as the primary
                      outcome, hazard ratios (HRs) and $95\%$ confidence intervals
                      $(95\%$ CI) were estimated from competing risk analyses
                      based on cause-specific Cox proportional hazards models and
                      further in sensitivity analyses using Fine-Gray proportional
                      subdistribution hazards models. For all-cause mortality as
                      the secondary outcome, Cox proportional hazards models were
                      used. Subgroup analyses were performed by sex, tumor
                      subsite, tumor stage, body mass index and time to CRC
                      diagnosis. Resistin was measured on a median of 4.8 years
                      before CRC diagnosis. During a median follow-up of 8.2
                      years, 474 deaths from CRC and 147 deaths from other causes
                      were observed. Resistin concentrations were not associated
                      with CRC-specific mortality (HRQ4vsQ1 = 0.95, $95\%$ CI:
                      0.73-1.23; Ptrend = .97; and HRper doubling of resistin
                      concentration = 1.00; $95\%$ CI: 0.84-1.19; P = .98) or
                      all-cause mortality. Results from competing risk
                      (sensitivity) analysis were similar. No associations were
                      found in any subgroup analyses. These findings suggest no
                      association between pre-diagnostic circulating resistin
                      concentrations and CRC-specific or all-cause mortality among
                      persons with CRC, and the potential insignificance of
                      resistin in CRC progression.},
      keywords     = {EPIC (Other) / colorectal cancer (Other) / mortality
                      (Other) / pre-diagnostic (Other) / resistin (Other) /
                      survival (Other)},
      cin          = {C020},
      ddc          = {610},
      cid          = {I:(DE-He78)C020-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:38200695},
      doi          = {10.1002/ijc.34830},
      url          = {https://inrepo02.dkfz.de/record/286989},
}